Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- EMA Delays Decision on Leqembi Due to Procedural Issues
March 25, 2024
- Iclusig Gets Additional FDA Nod for Iclusig in Ph+ ALL: Takeda
March 25, 2024
- Novartis, Sandoz Recall Entacapone Products over Carcinogenic Risk
March 25, 2024
- Kobayashi Pharma Recalls Supplements on Reports of Kidney Disorders
March 25, 2024
- Japan, US CROs to Collaborate to Address Drug Lags/Losses
March 22, 2024
- Astellas Gives 1.5% Pay Raise to Acquire Best Talents
March 22, 2024
- FDA Clears Orchard’s Lenmeldy Gene Therapy for MLD
March 22, 2024
- Will Kyowa Kirin’s Eye Drops for nAMD Replace Intraocular Injections? PII Now Underway
March 21, 2024
- Meiji’s Bivalent COVID Jab Hits Primary Goal in PIII Omicron Trial; New Strains Eyed
March 21, 2024
- Arexvy Already January GP Rep Promotion Champion, Tarlige Tops HP Ranking
March 21, 2024
- SanBio Chief Baffled by Planned Advisory Session over Lead Cell Therapy
March 21, 2024
- JCR Hits 1st Milestone in Alexion Collab for Neurodegenerative Disease
March 21, 2024
- Shonan iPark Launches Local Post in South Korea
March 19, 2024
- ASKA Ties Up with Red Arrow on Novel Preeclampsia Treatment
March 19, 2024
- Canaglu OD Tablet Version Approved in Japan
March 19, 2024
- FY2024 Revision Rates Tallied for Each Firm’s Top 5 Meds; Fuso Logs Price Hike Too on Infusion Products
March 18, 2024
- Sumitomo Offloads Entire Ulotaront Rights to Otsuka for Strategic Priorities
March 18, 2024
- BIKEN’s 5-in-1 Vaccine Reaches Market Too before NIP Inclusion
March 18, 2024
- Daiichi Sankyo Offers Hefty 7%-Plus Pay Hike in 2024
March 18, 2024
- Bimzelx’s 320 mg Auto-Injector Version Filed in Japan: UCB
March 18, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…